Mesoblast (MESO) had the highest return between March 25, 2024 and April 5, 2024 by a US stock with a market cap of $500M+, returning 177.5%.
| ASSET | DATE | % RETURN |
|---|---|---|
Mesoblast (MESO) | 3/25/2024 - 4/5/2024 | 177.51% |
Stoke Therapeutics (STOK) | 3/25/2024 - 4/5/2024 | 99.84% |
Ouster, Inc Common Stock (OUST) | 3/25/2024 - 4/5/2024 | 93.55% |
Oruka Therapeutics (ORKA) | 3/25/2024 - 4/5/2024 | 73.6% |
Nuvation Bio (NUVB) | 3/25/2024 - 4/5/2024 | 69.15% |
Root (ROOT) | 3/25/2024 - 4/5/2024 | 55.71% |
ATAI Life Sciences (ATAI) | 3/25/2024 - 4/5/2024 | 51.23% |
Cidara Therapeutics (CDTX) | 3/25/2024 - 4/5/2024 | 48.72% |
First Majestic Silver (AG) | 3/25/2024 - 4/5/2024 | 44.53% |
Nektar Therapeutics (NKTR) | 3/25/2024 - 4/5/2024 | 43.48% |
Semtech (SMTC) | 3/25/2024 - 4/5/2024 | 43.35% |
Coeur Mining (CDE) | 3/25/2024 - 4/5/2024 | 43.24% |
Qilian International (BGM) | 3/25/2024 - 4/5/2024 | 42.86% |
Nuscale Power (SMR) | 3/25/2024 - 4/5/2024 | 41.53% |
Opko Health (OPK) | 3/25/2024 - 4/5/2024 | 40.68% |
Avino Silver & Gold Mines (ASM) | 3/25/2024 - 4/5/2024 | 39.66% |
Hippo (HIPO) | 3/25/2024 - 4/5/2024 | 37.92% |
Real Brokerage (REAX) | 3/25/2024 - 4/5/2024 | 37.71% |
Fortuna Silver Mines (FSM) | 3/25/2024 - 4/5/2024 | 36.92% |
NRx Pharmaceuticals (NRXPW) | 3/25/2024 - 4/5/2024 | 33.33% |
STAAR Surgical (STAA) | 3/25/2024 - 4/5/2024 | 32.03% |
Evolv Technologies (EVLV) | 3/25/2024 - 4/5/2024 | 31.53% |
Yatsen (YSG) | 3/25/2024 - 4/5/2024 | 31.25% |
GCM Grosvenor (GCMGW) | 3/25/2024 - 4/5/2024 | 31.04% |
REX American Resources (REX) | 3/25/2024 - 4/5/2024 | 30.87% |
